Zhongke Xinfei is committed to innovative phage synthesis biology therapies to solve the increasingly severe problem of drug-resistant bacterial infections in clinical practice and improve the survival rate of patients with multidrug-resistant bacterial infections. Zhongke Xinfei has established multiple leading technology platforms, including synthetic biology phage modification platform and IBT fusion technology phage screening platform, which can quickly develop artificial phage products with stronger bactericidal effect, safer, and easier standardized preparation. The core team of the company has cooperated with multiple hospitals in China to use phage therapy to cure multiple critically ill patients with drug-resistant bacterial infections. In the future, the company plans to expand the application of bacteriophages in various fields such as medicine, beauty, and agriculture based on its accumulation in bacteriophage synthetic biology technology, establish a comprehensive business ecosystem for bacteriophage functional applications, and achieve global commercial leadership in this field.